ClinicalTrials.gg
RecruitingNCT04116541MegaMOSTUpdated Jul 8, 2026

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

A Phase 2 interventional study of HDM201 and Ribociclib in Malignant Solid Tumor, sponsored by Centre Leon Berard. Recruiting at 13 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Centre Leon Berard · Phase 2, Interventional, and Treatment

How we know · 17 judgments

From the registry’s dates

  • Started Jan 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
455
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing cabozantinib in Neoplasm Metastasis — 1 open to participants now, 3 under way, none of them phase 3. cabozantinib · Neoplasm Metastasis.

Planned enrollment
Largest of 17
455 · median 36
Started
2020
with 1 other
Phase 2
11 of 17
1 open now
Registered
10th of 17
by date
Lead sponsor
1 of 17
Centre Leon Berard

Among the 17 studies testing cabozantinib in Neoplasm Metastasis, this one has the largest planned enrollment, is one of 2 that started in 2020, is one of 11 in phase 2, and was the 10th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 17 studies testing cabozantinib in Neoplasm Metastasis is open now, in 1 country.

By country, each count listing its studies:

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing cabozantinib in Neoplasm Metastasis, or all of them as a file.
02

Study summary

This trial is a multicenter, open-label, biology driven, phase II study using a sequential Bayesian design, aiming to assess the efficacy and safety of different Matched Targeted Therapy (MTT) in independent and parallel cohorts of treatment.

Patients will be assigned to a treatment cohort based on molecular alterations/characteristics detected on tumor sample from primary tumor or metastatic lesion.

In this protocol, several MTTs treatment cohorts are planned. This study is designed with the flexibility to open new MTTs treatment cohorts and to close existing MTTs treatment cohorts that demonstrate no clinical benefit. Each treatment cohort will be driven separately even though procedures, quality control and reporting, will be common. The protocol will be amended in order to include new treatments or combinations that emerge as being of interest for patients with advanced/metastatic cancers.

All eligible patients will receive study drugs as long as patient experiences clinical benefit in the opinion of the investigator, or until unacceptable toxicity, or until symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status, or withdrawal of consent.

Patients will be permitted to continue study treatment after progressive disease according to RECIST v1.1 if they meet all of the following criteria and following validation of the Sponsor:

  • Evidence of clinical benefit as assessed by the investigators,
  • Absence of symptoms and signs (including worsening of laboratory values; e.g., new or worsening hypercalcemia) that indicate unequivocal progression of disease,
  • No decline in ECOG Performance Status (PS) that can be attributed to disease progression.
03

Conditions studied

  • Malignant Solid Tumor

Browse trials for

Keywords

  • Metastatic Solid Neoplasm
  • Advanced Solid Tumor
  • Genomic alteration
  • Targeted therapy
  • Cabozantinib
  • Ribociclib
  • HDM201
  • Alectinib
  • Trametinib
  • Dabrafenib
  • Avapritinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged of at least 18 years on day of signing .
  • Patients with confirmed diagnosis of disease or unresectable locally advanced that is resistant or to standard therapies or for which standard therapies does not exist or is/are not considered appropriate by the investigator.
  • A multidisciplinary molecular board must have recommended the specific MTT based on the following documented actionable alterations:

    • Cohort HDM201-Ribociclib : amplification of CDK6 and/or CDK4, and/or CDKN2A homozygous deletion, and/or amplification of CCND1 and/or CCND3 with no deletion/losses more than single copy of RB1 by copy number and P53 wild-type.
    • Cohort Cabozantinib : AXL, MET, VEGFR, VEGF, RET, ROS1, MER, TRKB, TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation and/or ROS1 translocation, and/or MET translocation.
    • Cohort Alectinib : Activating ALK alterations: translocation, or selected mutations, or activating rearrangements following validation by central molecular tumor board of Centre Léon Bérard.
    • Cohort Regoranib : Activating mutation and/or amplification and/or rearrangement of VEGFR1-3, TIE-2, KIT, RET, RAF1, BRAF (other than V600 mutations), CRAF, HRAS, PDGFR, FGFR1-2, FLT3 and/or CSFR1, and/or amplification of the ligands, and/or biallelic inactivation of SMAD4, following validation by central molecular tumor board of Centre Léon Bérard.
    • Cohort Trametinib : Activating mutation and/or amplification of KRAS (except all KRAS G12 mutations), NRAS, HRAS and/or MAP2K; and/or biallelic inactivation of NF1; and/or activating mutation PTPN11; and/or amplification or translocation of BRAF, and/or translocation RAF1
    • Cohort Trametinib + Dabrafenib : BRAF V600 mutation and/or rearrangement of BRAF following validation by central molecular tumor board of Centre Léon Bérard.
    • Cohort Avapritinib : Activating mutations of KIT exon 17 or PDGFRA exon 18 associated or not to mutation on KIT exon 11 or PDGFRA exon 12/14
  • Previously treated by at least one in the advanced/metastatic setting except for specific tumor type with no standard treatment approved and reimbursed in France following sponsor approval.
  • Documented radiological disease progression as per v1.1 and presence of at least one according to RECIST 1.1 criteria based on screening tumor assessment.
  • Performance Status score of 0 or 1 according to the (ECOG) scale.
  • Adequate organ function
  • Adequate cardiovascular function
  • Specific toxicities related to any prior anti-cancer therapy must have resolved to grade ≤1 , except for alopecia (all grades), grade 2 neuropathy or anemia.
  • Unless infertility is proven, men must agree to use effective
  • Women of must have a negative serum pregnancy test within 7 days of first dose of study drug and agree to use effective contraception
  • Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study procedures as per protocol.
  • Patient must be covered by a medical insurance.

Exclusion criteria

Exclusion Criteria:

  • Patients amenable to therapy with curative intent.
  • Patients participating to another clinical trial with a medicinal product.
  • Patients previously treated with similar MTT meaning any agent targeting the same signaling pathways components.
  • Patients unable to swallow oral medication.
  • Patients with known to
  • Patients with symptomatic central nervous system (CNS) who are neurologically unstable or require increasing doses of or local CNS-directed therapy to control their CNS disease.
  • Patients with secondary unless this malignancy is not expected to interfere with the evaluation of study endpoints and is approved by the sponsor. Examples of the latter include: basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, localized prostate cancer, prior malignancy and no evidence of recurrence for ≥ 2 years.
  • Patients using, or requirement to use while on the study, or not respecting the minimal of medications
  • Any and/or uncontrolled medical disease that could compromise the patient's ability to tolerate study drug or would likely interfere with study procedures or results.
  • Patients with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Patients who are pregnant or breastfeeding women or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through after the last dose of trial treatment (depanding on cohort).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
455 participants (estimated)

Study arms

  • Experimental
    HDM201 + Ribociclib

    Patient with documented amplification of Cyclin-dependent kinase 6 (CDK6) and/or Cyclin-dependent kinase 4 (CDK4), and/or cyclin dependent kinase inhibitor 2A (CDKN2A) homozygous deletion, and/or amplification of Cyclin D1 (CCND1) and/or Cyclin D3 (CCND3) with no deletion/losses more than single copy of retinoblastoma 1 (RB1) by copy number and P53 wild-type detected on tumor sample from primary tumor or metastatic lesion.

    Drug: HDM201 · Drug: Ribociclib

  • Experimental
    Cabozantinib

    Patient with AXL, MET, vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor (VEGF), RET, ROS1, MER, Tropomyosin receptor kinase B (TRKB),TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation and/or ROS1 translocation, and/or MET translocation detected on tumor sample from primary tumor or metastatic lesion.

    Drug: Cabozantinib

  • Experimental
    Alectinib

    Activating ALK alterations: translocation, or selected mutations,), or activating rearrangements following validation by central molecular tumor board of Centre Léon Bérard.

    Drug: Alectinib

  • Experimental
    Regorafenib

    Patient with Activating mutation and/or amplification and/or rearrangement of VEGFR1-3, TIE-2, KIT, RET, RAF1, BRAF (other than V600 mutations), CRAF, HRAS , PDGFR, FGFR1-2, FLT3 and/or CSF1R, and/or amplification of the ligands, and/or biallelic inactivation of SMAD4, following validation by central molecular tumor board of Centre Léon Bérard.

    Drug: Regorafenib

  • Experimental
    Trametinib

    Patient with activating mutation and/or amplification of KRAS (except all KRAS G12 mutations), NRAS, HRAS and/or Mitogen-Activated Protein Kinase Kinase (MAP2K); and/or biallelic inactivation of Neurofibromin 1 (NF1); and/or activating mutation Protein Tyrosine Phosphatase Non-Receptor Type 11 (PTPN11); and/or amplification or translocation of BRAF ; and/or translocation RAF1

    Drug: Trametinib

  • Experimental
    Trametinib + Dabrafenib

    Patient with BRAF V600 mutation and/or rearrangement of BRAF following validation by central molecular tumor board of Centre Léon Bérard

    Drug: Trametinib · Drug: Dabrafenib

  • Experimental
    Avapritinib

    Activating mutations of KIT exon 17 or PDGFRA exon 18 associated or not to mutation on KIT exon 11 or PDGFRA exon 12/14

    Drug: Avapritinib

Interventions

  • DrugSiremadlinStudies of SiremadlinSiremadlin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    HDM201 120mg, Every 3 weeks, Per os

    Also known as: Closed cohort

  • Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os

    Also known as: Closed cohort

  • Cabozantinib, 60 mg /day, continuous, Per os

    Also known as: Closed cohort

  • Alectinib, 600mg twice daily, Per os

    Also known as: Open cohort

  • Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os

    Also known as: Closed cohort

  • Trametinib 2 mg/day, continuous, Per os

    Also known as: Closed cohort

  • Dabrafenib 150 mg twice daily, Per os

    Also known as: Open cohort

  • 300 mg/day,continuous, Per os

    Also known as: Open cohort

06

What researchers measure

Primary outcomes

  1. Progression free rate after 3 months (12 weeks) of treatment

    The proportion of patients with a complete response (CR), a partial response (PR) or a stable disease (SD) at 3 months (12 weeks).

    Time frame: 3 months (12 weeks)

Secondary outcomes

  1. Objective response rate after 3 months (12 weeks) of treatment

    The proportion of patients with a complete or a partial response (CR or PR) as best overall response at 3 months (12 weeks).

    Time frame: 3 months (12 weeks)

  2. Duration of Response

    Duration of response applies only to patients whose best overall response was a complete response or a partial response (CR or PR). It will be defined as the time from the date of first documented response (CR or PR) to the date of the first documented progression or death due to underlying cancer and censored at the date of the last adequate tumor assessment.

    Time frame: Up to 3 years

  3. Progression Free Survival

    The time from the date of the first study drug administration to the first documented progression according to investigator assessment of RECIST version 1.1 or death due to any cause

    Time frame: Up to 3 years

  4. Overall survival

    The time from the date of the first study drug administration to the date of death due to any cause

    Time frame: Up to 3 years

  5. Percentage of long-term responders (> 6 months)

    The proportion of long term responders (\> 6 months)

    Time frame: 6 months

  6. Adverse Events

    Nature, frequency and severity of Adverse Events (AEs), Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) graded using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.

    Time frame: Up to 3 years

07

Study locations

9 of 13 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Oct 2026, 81 months after the start.

Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's planned 81 months is above that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2019
First posted
Oct 4, 2019
StartActual
Jan 28, 2020
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2027
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04116541
Lead sponsor
Centre Leon Berard
Responsible party
Sponsor
First posted
Oct 4, 2019
Start date
Jan 28, 2020
Primary completion
Oct 2026 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jul 8, 2026

Study contacts

Jean-Yves BLAY, MD
Contact
jean-yves.blay@lyon.unicancer.fr
+33478785126
Olivier TREDAN, MD
Contact
olivier.tredan@lyon.unicancer.fr
+33478782828
Jean-Yves BLAY, MD
principal investigator · Centre Leon Berard

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Siremadlin · Cabozantinib · Alectinib · Regorafenib · Trametinib · Dabrafenib · Avapritinib

Start the discussion